We are live on ! Find out more
CVS icon

CVS Health

1,654 hedge funds and large institutions have $54.6B invested in CVS Health in 2019 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 754 increasing their positions, 660 reducing their positions, and 154 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more funds holding in top 10

Funds holding in top 10: 3548 (+13)

14% more repeat investments, than reductions

Existing positions increased: 754 | Existing positions reduced: 660

1% less capital invested

Capital invested by funds: $55.1B → $54.6B (-$425M)

1.44% less ownership

Funds ownership: 78.75%77.31% (-1.4%)

3% less funds holding

Funds holding: 1,7081,654 (-54)

20% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 154

20% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.44B

Holders
1,654
Holders Change
-54
Holders Change %
-3.16%
% of All Funds
35.92%
Holding in Top 10
48
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+37.14%
% of All Funds
1.04%
New
123
Increased
754
Reduced
660
Closed
154
Calls
$1.14B
Puts
$1.44B
Net Calls
-$291M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
SCP
526
Shorepoint Capital Partners
Massachusetts
$4.2M -$383K -7,121 -8%
RIM
527
Redpoint Investment Management
Australia
$4.19M -$568K -10,545 -12%
OI
528
Oakbrook Investments
Illinois
$4.19M +$66.9K +1,243 +2%
COPPSERS
529
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$4.16M +$23.4K +435 +0.6%
CCM
530
Cobalt Capital Management
New Jersey
$4.14M +$4.09M +76,000 New
HAI
531
Hennessy Advisors Inc
California
$4.13M
CC
532
Courier Capital
New York
$4.11M -$5.87K -109 -0.1%
WPIC
533
White Pine Investment Company
Michigan
$4.11M +$4.06M +75,330 New
CNBT
534
Canandaigua National Bank & Trust
New York
$4.09M +$1.1M +20,373 +37%
KHLMVGHM
535
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Israel
$4.08M +$4.04M +74,954 New
LCC
536
Lincoln Capital Corp
Rhode Island
$4.08M +$5.33K +99 +0.1%
SWP
537
Stratos Wealth Partners
Ohio
$4.01M +$357K +6,624 +10%
FTC
538
Farmers Trust Company
Ohio
$4M +$257K +4,772 +7%
SMDAM
539
Sumitomo Mitsui DS Asset Management
Japan
$3.97M -$1.19M -22,012 -23%
Schroder Investment Management Group
540
Schroder Investment Management Group
United Kingdom
$3.97M -$22.2M -411,600 -85%
EGM
541
Engineers Gate Manager
New York
$3.95M +$1.15M +21,345 +42%
PWW
542
Pettyjohn Wood & White
Virginia
$3.93M -$65.6K -1,218 -2%
AWM
543
Arbor Wealth Management
Florida
$3.93M +$3.88M +72,058 New
GCM
544
Gibraltar Capital Management
Oklahoma
$3.85M +$460K +8,548 +14%
NSIM
545
North Star Investment Management
Illinois
$3.85M +$747K +13,864 +24%
DAM
546
Deltec Asset Management
New York
$3.84M -$3.2M -59,500 -46%
BF
547
BOK Financial
Oklahoma
$3.81M +$321K +5,961 +9%
RIM
548
Regent Investment Management
Kentucky
$3.81M -$102K -1,900 -3%
MIA
549
MainStreet Investment Advisors
Illinois
$3.8M +$3.76M +69,766 New
PLFAM
550
Pineno Levin & Ford Asset Management
Virginia
$3.8M +$1.5M +27,825 +66%

CVS Hedge Fund Activity: Q2 2019 in Review

1,654 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2019, worth a combined $54.6B — down 0.77% from $55.1B a quarter earlier.

Sellers outnumbered buyers: 154 funds closed out of CVS and 123 opened new positions — a net loss of 31 holders — while 660 trimmed existing stakes and 754 added.

The largest buyer was Nuveen, adding an estimated $648M. The largest seller was T. Rowe Price Associates, cutting an estimated $321M.

  • 1,654 institutional investors held CVS Health (CVS) as of Q2 2019, down from 1,708 in Q1 2019.
  • Funds reported $54.6B of CVS Health stock for Q2 2019, down 0.77% quarter-over-quarter.
  • 123 funds opened new CVS Health positions in Q2 2019 and 154 closed out, a net change of -31 holders.
  • The largest CVS Health buyer in Q2 2019 was Nuveen, an estimated $648M added.
  • The largest CVS Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $321M sold.

Based on aggregated 13F filings for Q2 2019.